KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Current Leases: 2019-2024

Historic Current Leases for Xenon Pharmaceuticals (XENE) over the last 6 years, with Dec 2024 value amounting to $1.4 million.

  • Xenon Pharmaceuticals' Current Leases rose 7.79% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 7.79%. This contributed to the annual value of $1.4 million for FY2024, which is 5.39% up from last year.
  • Latest data reveals that Xenon Pharmaceuticals reported Current Leases of $1.4 million as of FY2024, which was up 5.39% from $1.3 million recorded in FY2023.
  • Xenon Pharmaceuticals' 5-year Current Leases high stood at $1.4 million for FY2024, and its period low was $265,000 during FY2020.
  • Its 3-year average for Current Leases is $1.1 million, with a median of $1.3 million in 2023.
  • Its Current Leases has fluctuated over the past 5 years, first fell by 19.34% in 2022, then skyrocketed by 166.19% in 2023.
  • Xenon Pharmaceuticals' Current Leases (Yearly) stood at $265,000 in 2020, then soared by 128.30% to $605,000 in 2021, then fell by 19.34% to $488,000 in 2022, then skyrocketed by 166.19% to $1.3 million in 2023, then increased by 5.39% to $1.4 million in 2024.